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Abstract
Background: Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC) that may
cause aneurism-related haemorrhages and renal impairment. Everolimus has emerged as an alternative to surgery/
embolization. We provide further insight into everolimus safety and efficacy for TSC-related AML.
Methods: This was a Spanish expanded access trial including patients aged ≥18 years with TSC-related AML.
They received 10 mg everolimus once daily until AML progression, unacceptable toxicity, death/withdrawal,
commercialisation for TSC-related AML, or 1 year after first patient enrolment. The primary outcome was
dose-limiting safety according to grade 3/4 adverse events, serious adverse events, or adverse events leading
to treatment modification. Secondary outcomes included overall safety and efficacy.
Results: Nineteen patients were enrolled and received everolimus for a median of 6.6 (5.3–10.9) months. Eleven
(57.9 %) remained on 10 mg/day throughout the study and eight (42.1 %) required treatment modifications due to
adverse events; none permanently discontinued treatment. Adverse events were overall grade 1/2 and most
frequently included aphthous stomatitis/mucosal inflammation, hypercholesterolaemia/hypertriglyceridaemia,
urinary tract infection, hypertension, dermatitis acneiform, and insomnia. Four (21.1 %) patients experienced grade 3
adverse events, none was grade 4, and only one (5.3 %) was serious (pneumonia). AML volume was reduced ≥30 %
in 11 (57.9 %) patients and ≥50 % in 9 (47.4 %); none progressed. Right and left kidney sizes decreased in 16 and
14 patients, respectively.
Conclusions: These findings support the benefit of everolimus for renal AML due to a manageable safety profile
accompanied by reduced AML and kidney volumes.
Trial registration: EudraCT number 2012-005397-63; date of registration 22 Nov 2012.
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Background
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant genetic disorder usually caused by mutations in
either the TSC1 or TSC2 genes [1, 2] and which affects
one in about 8000 to 12,900 individuals [3, 4]. These
mutations spearhead mammalian target of rapamycin
(mTOR) activation, leading to uncontrolled cellular
proliferation [5]. The disease is characterized by neuro-
cognitive deficits and growth of non-malignant tumours
called hamartomas in several body locations, including
renal angiomyolipomas (AML) in up to 80 % of patients
along with other manifestations [6]. These AML are
mesenchymal tumours composed of abnormal blood
vessels, immature smooth muscle cells and adipose
tissue [7]. They usually appear in childhood and their
progressive enlargement leads to a high risk of bleeding
and may sometimes encroach on the renal parenchyma
causing renal failure [7]. Unlike sporadic renal AML,
TSC-related AML tends to be larger, multiple, and at
higher risk of bleeding [8]. The main goals of treating
patients with renal AML are preserving kidney function
and preventing complications such as haemorrhages.
Surgical procedures or embolization has been used to
manage large, symptomatic, and/or bleeding AMLs, but
mTOR inhibitors have now emerged as a non-invasive
treatment alternative [9].
Everolimus is an orally bioavailable mTOR inhibitor
that induces cell cycle arrest, reduces cell proliferation,
and prompts angiogenesis regression, contributing to
suppress the enlargement of tumours and promoting
their regression [10, 11]. Everolimus has demonstrated
clinical activity across a variety of tumours, leading to its
approval for malignancies such as hormone receptor-
positive advanced breast cancer, neuroendocrine tu-
mours of pancreatic origin and renal cell carcinoma
[12]. The EXIST-2 phase III trial investigated the use of
everolimus for renal AML associated with TSC [13]. It
was a randomized, double-blind, placebo-controlled trial
that demonstrated the efficacy of everolimus administra-
tion to adult patients with TSC-related AML, showing
that over half of patients experienced at least a 50 % re-
duction in AML volume after just 6 months of treatment
[13]. The efficacy and manageable safety profile seen in
this trial were consistent with those observed in its sub-
sequent extension phase [14]. In addition, everolimus
safety appeared to be similar to that previously reported
in other TSC populations [15–18] and did not give rise
to safety concerns with regard to its use for different
solid tumours [11]. This positive benefit/risk balance
supported the use of everolimus for TSC-related renal
AML and was the basis for requesting the European
Medicines Agency’s authorization for this indication.
In light of the above, we decided to conduct an ex-
panded access trial to provide further insight into the
safety and efficacy of everolimus for the management of
renal AML associated with TSC in Spain.
Methods
This trial was conducted in accordance with the World
Medical Association Declaration of Helsinki, all its
amendments, and national regulations. It was approved by
the ethics committee of Fundació Puigvert (Barcelona,
Spain) and all patients gave their written informed consent
prior to any study procedure.
Patient population
This study included all patients meeting selection cri-
teria who agreed to participate and were consecutively
recruited between May 2013 and May 2014. The main
inclusion criteria comprised patients aged 18 years or
older, with at least one renal AML of 3 cm or larger in
its longest diameter as per computed tomography (CT)
or magnetic resonance imaging (MRI), and a definite
diagnosis of TSC. This diagnosis was based on the mo-
dified Gomez criteria [19, 20]. Patients whose AML
required surgery at enrolment were excluded, as well as
those with AML-related bleeding or embolisation during
the 6 months prior to enrolment. Other exclusion
criteria mainly included previous history of heart attack,
angina pectoris, haemorrhagic stroke related to athero-
sclerosis, impaired lung functioning, organ transpla-
ntation, or any surgery within the 2 months prior to
enrolment, and also the presence of significant haema-
tological/hepatic abnormality, serum creatinine levels
higher than 1.5 times the upper limit of normal, haemor-
rhagic diathesis or treatment with vitamin K antagonists
(except for low-dose warfarin), uncontrolled hyperlipid-
aemia/diabetes, other uncontrolled/severe disease that
might cause unacceptable safety risks, or any ongoing/
active infection (except for hepatitis B/C virus infection)
at study enrolment.
Study design and treatment
This was an open-label, single-arm, phase IIIb, expanded
access trial carried out at 12 Spanish hospitals. Screening
and baseline assessments were conducted over the 21 days
prior to the first dose of everolimus (Fig. 1). Eligible patients
then started once-daily oral administration of everolimus at
a dose of 10 mg/day after signing the informed consent.
Everolimus was administered until AML progression,
occurrence of unacceptable toxicity according to investiga-
tor’s criteria, patient death or withdrawal for any reason.
Another criterion to stop the trial was everolimus commer-
cialisation for TSC-related AML in Spain, or 1 year after
first patient enrolment; the latter was what occurred first.
Treatment modifications were determined clinically on the
basis of safety findings (i.e. according to the grade of
adverse events as per the Common Terminology Criteria
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for Adverse Events (CTCAE) of the National Cancer Insti-
tute version 4.03 [21]), including dose adjustments, tempor-
ary treatment interruptions or permanent treatment
discontinuation. Initial doses of 10 mg/day could be low-
ered to 5 mg/day (dosing level −1) or even to 5 mg/every
other day (dosing level −2).
Prophylactic antiviral treatment was recommended in
patients with detectable hepatitis B virus DNA or surface
antigen, although there were none. The use of antiprolif-
erative agents or investigational drugs other than the
study treatment was prohibited. Concomitant use of
moderate/strong inhibitors or strong inducers of cyto-
chrome P450 3A4 was to be avoided, as well as the use
of p-glycoprotein inhibitors and attenuated vaccines.
There were no further restrictions with regard to con-
comitant medication.
Toxicity of study treatment was continuously assessed
according to adverse events reported in every monthly
follow-up until 28 days post-treatment. All adverse
events were coded using the Medical Dictionary for
Regulatory Activities (MedDRA) preferred term and
graded as per the CTCAE of the National Cancer Insti-
tute version 4.03 [21]. Their relationship with everolimus
was categorized as non-related, unlikely, possibly, likely,
or definitively related. AML response/progression was
assessed by kidney CT/MRI. Local radiologists assessed
measurable (longest diameter ≥1 cm) and non-measurable
(longest diameter <1 cm) lesions at baseline, and at
months 3, 6, and 12/end of treatment; for each patient,
the same kidney imaging modality was used throughout
the study. Radiologic response was defined as ≥50 % re-
duction from baseline in the sum of volumes of all target
lesions (≤5 largest lesions with longest diameter ≥1 cm),
confirmed in a second scan performed approximately
12 weeks later (no sooner than 8 weeks later), and in the
absence of new lesions with longest diameter ≥1 cm, kid-
ney volume increase >20 % from nadir, and AML-related
grade ≥2 bleeding or need for embolisation/surgery.
Radiologic progression was defined as ≥25 % increase
from nadir in the sum of volumes of all target lesions and/
or ≥20 % increase from nadir in the volume of either
kidney with a value greater than baseline, appearance
of new lesions with longest diameter ≥1 cm, and/or
AML-related grade ≥2 bleeding or need for embolisa-
tion/surgery. Volume of each kidney was measured by
CT/MRI to assess changes in non-target/non-measur-
able AML lesions.
Statistical analysis
The primary outcome was dose-limiting safety according
to the incidence of grade 3/4 adverse events, serious ad-
verse events, and those leading to changes in the admin-
istration of everolimus (i.e. dose change, interruption, or
discontinuation). Secondary outcomes included the over-
all safety of everolimus based on the incidence of any-
grade adverse events and its efficacy according to the
AML response rate. Descriptive analyses of patient char-
acteristics and outcomes were conducted, including cen-
tral tendency and dispersion (mean ± standard deviation
[SD], or median [interquartile range, IQR]) for quantita-
tive variables, and frequency distribution (absolute fre-
quencies and valid percentages) for qualitative variables.
Missing data were not considered in the analyses, which
were performed with the Statistical Package for the
Social Sciences version 19 (SPSS Inc, Chicago, USA) and
R version 2.15.0 (The R Foundation, Vienna, Austria).
Informed consent
Selection criteria
Demographics
Medical history
Comorbidities
Clinical examination
Clinical laboratory analyses
Kidney CT/MRI
Concomitant medication
Screening/baseline 
assessments
(≤ 21 days pre-treatment)
Study treatment administration
Clinical examination
Clinical laboratory analyses
Kidney CT/MRI (months 3, 6, 12/end of treatment)
Concomitant medication
Adverse events
Everolimus administration
(until progression, unacceptable toxicity, death, 
withdrawal, everolimus commercialisation for this 
condition, or one year after first patient enrolment)
Concomitant medication
Adverse events
Post-treatment safety 
follow-up
(28 days post-treatment)
Fig. 1 Overall flow chart and main study assessments. Abbreviations: CT computed tomography, MRI magnetic resonance imaging
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Results
Patient characteristics
A total of 20 patients were assessed for eligibility, one of
whom was considered a screening failure as a result of suf-
fering from an uncontrolled/severe disease that might have
caused unacceptable safety risks. Therefore, 19 patients
were finally enrolled and received the study treatment.
Their median (IQR) age was 38.0 (29.0–43.0) years
and more than a half (68.4 %) were females (Table 1).
They showed a median (IQR) sum of volumes of all
target renal AML lesions of 260.0 (127.8–322.2) cm3;
volumes of right and left kidneys reached 329.4 (193.0–
979.7) cm3 and 299.0 (184.2–404.7) cm3, respectively.
Everolimus exposure
The median (IQR) duration of everolimus exposure was
6.6 (5.3–10.9) months. The weighted mean (±SD) dose
was 9.1 ± 1.4 mg/day and the mean (±SD) accumulated
dose reached 2123.0 ± 995.2 mg.
Eleven (57.9 %) patients received 10 mg/day of everoli-
mus over the whole study duration. The remaining eight
(42.1 %) patients required at least a dose reduction or
temporary interruption of treatment. No patient per-
manently discontinued the study treatment.
Safety outcomes
Primary safety outcome
A total of four (21.1 %) patients experienced five grade 3
adverse events, all of which were non-serious (Table 2).
They included an increase in transaminases likely related
to everolimus that led to the temporary interruption of
treatment, hypertriglyceridaemia likely related to everoli-
mus that required no therapeutic action, hypertriglyceri-
daemia definitively related to everolimus that required
concomitant medication, hypertension likely related to
everolimus that also required concomitant medication,
and mucosal inflammation definitively related to everoli-
mus that led to the temporary interruption of treatment.
No grade 4 adverse event was reported.
Only one (5.3 %) patient reported a serious adverse
event, which was a grade 2 pneumonia considered de-
finitively related to everolimus and that led to the
temporary interruption of treatment (Table 2).
Treatment modifications resulting from adverse events
were reported in eight (42.1 %) patients: dose reductions
Table 1 Baseline patient characteristics (N = 19)
Patient characteristics Value
Age (years), median (IQR) 38.0 (29.0–43.0)
Sex, n (%)
Female 13 (68.4)
Male 6 (31.6)
Race, n (%)
White 19 (100)
Main comorbidities, n (%)a
Hypertension 3 (15.8)
Asthma 2 (10.5)
Hypercholesterolaemia 2 (10.5)
Major features for TSC diagnosis, n (%)a
Renal AML 19 (100)
Facial angiofibromas/forehead plaque 15 (79.0)
Cortical tuber 10 (52.6)
Hypomelanotic macules (≥3) 7 (36.8)
Subependymal nodule 7 (36.8)
Non-traumatic ungual/periungual fibroma 4 (21.1)
Single/multiple cardiac rhabdomyoma 4 (21.1)
Lymphangiomyomatosis 3 (15.8)
Connective tissue nevus 2 (10.5)
Minor features for TSC diagnosis, n (%)a
Multiple renal cysts 11 (57.9)
Multiple randomly distributed pits
in dental enamel
3 (15.8)
Bone cysts 3 (15.8)
Non-renal hamartoma 2 (10.5)
“Confetti” skin lesions 1 (5.26)
Sum of volumes of target renal AML
lesions (cm3), median (IQR)
260.0 (127.8–322.2)
Volume of right kidney (cm3), median (IQR) 329.4 (193.0–979.7)b
Volume of left kidney (cm3), median (IQR) 299.0 (184.2–404.7)c
Abbreviations: AML angiomyolipoma, IQL interquartile range, SD standard
deviation, TSC tuberous sclerosis complex
aMultiple response variable
bOne patient had previously undergone nephrectomy of right kidney and two
had technical problems for renal volume assessment; N = 16
cThree patients had previously undergone nephrectomy of left kidney and one
had technical problems for renal volume assessment; N = 15
Table 2 Dose-limiting safety (N = 19)
Outcome n (%)
Patients with grade 3/4 adverse events 4 (21.1)a
Patients with serious adverse events 1 (5.3)b
Patients with adverse events leading to treatment
modification:
8 (42.1)
Adverse events leading to dose reduction 3 (15.8)
Adverse events leading to temporary treatment
interruption
3 (15.8)
Adverse events leading to dose reductions and temporary
treatment interruption
2 (10.5)
Adverse events leading to permanent treatment
withdrawal
0 (0.0)
All adverse events were graded as per the Common Terminology Criteria for
Adverse Events (CTCAE) of the National Cancer Institute (version 4.03)
aFour patients experienced five grade 3 adverse events (i.e. transaminases
increased n = 1, hypertriglyceridaemia n = 2, hypertension n = 1, mucosal
inflammation n = 1); no grade 4 adverse event was reported
bThe only serious adverse event was grade 2 pneumonia
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in three (15.8 %), temporary treatment interruptions in
another three (15.8 %), and both dose reduction and
temporary treatment interruption in two (10.5 %)
(Table 2). The reasons for dose reductions included
menorrhagia, anaemia, hypercholesterolaemia, hypertri-
glyceridaemia, hypertension, and investigator’s decision
due to accumulated adverse events rather than a specific
event. The reasons for temporary treatment interruption
encompassed gamma-glutamyltransferase increased, pneu-
monia, polypectomy, herpes zoster, mucosal inflammation,
transaminases increased, and erythema.
Secondary safety outcome
All patients showed at least one of the 158 reported
adverse events, regardless of relationship to study drug
(adverse events of any cause). They were mostly grade 1/
2 in severity and most frequently included (>25 % of
patients): aphthous stomatitis, hypercholesterolaemia,
hypertriglyceridaemia, urinary tract infection, mucosal
inflammation, hypertension, dermatitis acneiform, and
insomnia (Table 3).
Overall, 18 (94.7 %) patients reported 106 adverse
events suspected to be everolimus related (i.e. possibly,
likely, or definitively related). They were mostly grade 1/
2 and most commonly included (>25 % of patients):
aphthous stomatitis (n = 11, 57.9 %), hypercholesterol-
aemia (n = 11; 57.9 %, grade 1 in five patients and
grade 2 in six patients), hypertriglyceridaemia (n = 8;
42.1 %), urinary tract infection (n = 6; 31.6 %), muco-
sal inflammation (n = 7; 36.8 %), and dermatitis acnei-
form (n = 5; 26.3 %).
A total of 45 infections were observed in 14 (73.7 %)
patients, which were grade 1/2 and affected the oral
cavity (n = 16), respiratory tract (n = 12), urinary tract
(n = 8), skin (n = 7), and eyes (n = 2). Only two renal
adverse events were reported, including grade 1 pro-
teinuria (i.e. 1+ proteinuria; urinary protein <1.0 g/
24 h) (n = 1) and polyuria (n = 1); neither haemor-
rhage of renal AML nor increase of creatinine levels
was reported. Amenorrhoea was reported in three pa-
tients, which accounted for 27.3 % of 11 pre-menopausal
females and was grade 1 in all cases (i.e. intermittent men-
ses with skipped menses for no more than 1 to 3 months);
it was recovered in two patients and remained ongoing at
the end of the study in another, who developed it 1 month
before the study completion. Regarding hypercholesterol-
aemia: no action was taken in two patients (grade 1), there
was no study treatment interruption/discontinuation in
any patient, and a concomitant treatment was reported in
nine patients.
Efficacy outcomes
Nine (47.4 %) patients reported radiologic response of
renal AML, with a median (IQR) time from everolimus
initiation to the response assessment of 3.3 (3.0–6.2)
months. Ten (52.6 %) patients remained stable (i.e. nei-
ther radiologic response nor progression) and none
showed AML progression.
The sum of volumes of all target AML lesions de-
creased in 16 (84.2 %) patients, including ≥30 % reduc-
tion from baseline in 11 (57.9 %) patients and ≥50 % in
nine (47.4 %) patients; the proportion of patients achiev-
ing ≥30 % and ≥50 % reduction from baseline in each
study visit is summarized in Fig. 2. Only three (15.8 %)
patients report increased volumes, which were lower
than 15 % in all cases.
The volume of right kidney was reduced in 16 pa-
tients; no data was available on right kidney volume in
three patients (two due to technical problems and one
due to nephrectomy). The volume of left kidney de-
creased in 14 patients and only one patient showed
increased left kidney volume, which was lower than
20 %; no data was available in four patients (one due to
technical problems and three due to nephrectomy).
Discussion
This phase IIIb expanded access trial supports the bene-
fit of everolimus administration to adult patients with
TSC-related renal AML, due to a manageable safety
profile accompanied by reduced AML lesions and kidney
volumes. The overall safety profile was as expected
according to previously described adverse events experi-
enced by patients with TSC during everolimus admi-
nistration [13–18]. Oral mucosal inflammation with/
without aphthae, hypercholesterolaemia, hypertriglyceri-
daemia and infections such as those of the urinary tract
were reported among the most frequent adverse events.
These were mostly mild to moderate and could be
appropriately managed without everolimus discontinu-
ation, with decreased dose and/or adjunctive therapy.
Indeed, initial everolimus administration was maintained
in nearly 60 % of patients and it could be continued in
the remaining patients after dose reductions and/or
transient interruptions. Although the occurrence of
grade 3/4 adverse events might have jeopardized the
administration of everolimus, only five grade 3 and no
grade 4 events were reported over the study duration
and most of them could be appropriately managed with
concomitant medication or just observation; only two
required temporary treatment interruptions. Furthermore,
only one patient reported a serious adverse event, a case
of pneumonia that also led to temporary treatment inter-
ruption. These results are consistent with data reported by
the EXIST-2 trial on the administration of everolimus to
adult patients with TSC-related AML [13, 14] and other
trials including the EXIST-1 on everolimus administration
to adult/child patients with other TSC-related tumours
[15–18]. Adverse events have usually been reported in
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these trials in a considerable percentage of patients over
the first year of administration; however, they were mostly
grade 1/2 in severity and few were serious. In addition,
adverse events were usually handled with concomitant
medications and/or dose reductions/interruptions, this
making treatment discontinuation an infrequent need.
Inflammation of the mucous membranes of the oral cavity
with/without the formation of oral ulcerations are usual
and potentially dose-limiting events during everolimus
administration that may appear in 70 to 100 % of patients
receiving this agent for TSC-related tumours [13–18]. In
addition, the immunosuppressive properties of everolimus
may also increase susceptibility to localized or systemic
infections, which may occur in 65 to 100 % patients
[13–18]; however, clinical and therapeutic drug moni-
toring of patients under everolimus treatment may consid-
erably limit its consequences and improve patients’ safety.
The minimum dose necessary to maintain target everoli-
mus plasma levels may avoid over treatment and therefore
may limit some adverse events. Previously conducted
studies have reported the occurrence of certain adverse
events such as infections not only in patients receiving
Table 3 Adverse events of any cause experienced by ≥10 % patients over the study (N = 19)
Adverse event, n (%) All grades Grade 1 Grade 2 Grade 3
Aphthous stomatitis 11 (57.9) 11 (57.9) 0 (0.0) 0 (0.0)
Hypercholesterolaemia 11 (57.9) 5 (26.3) 6 (31.6) 0 (0.0)
Hypertriglyceridaemia 8 (42.1) 3 (15.8) 3 (15.8) 2 (10.5)
Urinary tract infection 8 (42.1) 2 (10.5) 6 (31.6) 0 (0.0)
Mucosal inflammation 7 (36.8) 5 (26.3) 1 (5.3) 1 (5.3)
Hypertension 6 (31.6) 3 (15.8) 2 (10.5) 1 (5.3)
Dermatitis acneiform 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0)
Insomnia 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0)
Catarrh 4 (21.1) 4 (21.1) 0 (0.0) 0 (0.0)
Diarrhoea 4 (21.1) 3 (15.8) 1 (5.3) 0 (0.0)
Amenorrhoea 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0)
Asthenia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0)
Headache 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0)
Dysgeusia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0)
Pharyngitis 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0)
Nasopharyngitis 3 (15.8) 2 (10.5) 1 (5.3) 0 (0.0)
Cough 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0)
Menstrual disorder 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0)
Conjunctivitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Dermatitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Back pain 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Abdominal pain upper 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Epistaxis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Erythema 2 (10.5) 1 (5.3) 1 (5.3) 0 (0.0)
Rash 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Oral herpes 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Dizziness 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Menorrhagia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Myalgia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Pyrexia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Vomiting 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0)
Gamma-glutamyltransferase increased 2 (10.5) 0 (0.0) 2 (10.5) 0 (0.0)
Transaminases increased 2 (10.5) 0 (0.0) 1 (5.3) 1 (5.3)
All adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) preferred term and graded as per the Common Terminology
Criteria for Adverse Events (CTCAE) of the National Cancer Institute (version 4.03)
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everolimus but also in those receiving placebo [13–16],
which raises the issue of whether there is a predisposing
effect of the disease that needs to be clarified in future
studies. Metabolic events such as hypercholesterolaemia,
hypertriglyceridaemia are other potential risks associated
with everolimus treatment that have been reported in 11
to 42 % of patients [13, 14, 17, 18], which may require
corrective measurements including dietary adjustments
and/or cholesterol lowering medication to prevent any
potential long-term cardiovascular effects. Furthermore,
amenorrhoea has recently emerged as a potential adverse
event affecting 13 to 38 % at-risk females during everoli-
mus administration [13–16]. Although its relationship to
everolimus is undergoing investigation, it reinforces the
need for further surveillance in women of childbearing po-
tential, though pregnancy must be avoided while on treat-
ment. Our female population was two-thirds of the overall
population, most of which were pre-menopausal, and
though yet the prevalence of AML in females and males
in TSC seems to be equal, it should be clarified if females
have an increased risk of AML. Furthermore, despite
the fact that only one patient reported proteinuria, a
more systematic assessment of proteinuria/albumin-
uria should be considered in future studies to confirm
our findings.
Everolimus administration to patients with TSC-
related AML over the extension phase of the EXIST-
2 trial supports a long-term adverse event profile
consistent with previously established risks and with
no new safety concerns [14]. In addition, the incidence of
adverse events markedly decreased over time, with the
highest incidence over the first year of treatment, then de-
clining and reaching rates lower than 10 % in most ad-
verse events over the second year and even lower over the
third year [14]. The decreasing incidence of adverse events
and the fact that most of them could be managed success-
fully through dose reductions/interruptions support the
importance of careful monitoring and effective manage-
ment to optimize patient safety and treatment outcomes.
An acceptable safety profile is absolutely needed in this
setting, as young adults may be treated lifelong and in-
creased cardiovascular risk should be avoided.
Continued exposure to everolimus has shown to pro-
vide a sustained reduction of TSC-related renal AML
lesions over time [14]. These effects may become evident
a few months after starting therapy, with a median time
to AML response for everolimus of nearly 3 months
[13, 14]. The rapid clinical activity of everolimus was
especially important in our patient population, which
showed large AMLs and were therefore at risk of compli-
cations. Indeed, most patients achieved benefits in terms
of reducing renal AML lesions and kidney volumes after a
median of 3.3 months of therapy, without exhibiting
AML-related complications such as haemorrhages or de-
terioration of renal functioning over the whole study
follow-up. These data are in line with the renal AML
shrinkage shown by previous trials and support the
achievement of greater benefits after longer administra-
tion periods [13, 14], which may even reach up to 86.4 %
of patients achieving AML reductions ≥30 % over the
first 3 years of treatment [14]. This AML reduction
also supports the role of everolimus as a therapeutic
alternative to traditional therapies such as selective ar-
terial embolization, which often lead patients to need
further embolisations or even nephrectomy in the long-
term [22]. In addition, AML shrinkage over everolimus
administration appears to occur irrespective of age, gen-
der, and race [13, 16], and levels of plasma angiogenic
markers such as endothelial growth factor D or collagen
type IV seem to be associated with response to everolimus
[23]. However, further studies are still needed to assess
other patient characteristics and/or biomarkers that enable
the magnitude of response to be optimized when tailoring
treatment to patients with TSC-related renal AMLs, as well
as determining the most appropriate treatment duration to
maximize and prolong everolimus’ effect over time.
The safety and efficacy of everolimus administration for
TSC-related AML evidenced in our trial is in line with
our previous experience with sirolimus use in this condi-
tion. The findings derived from our previous 24-month
phase II-III study carried out in 17 patients with TSC-
related AML also evidenced an acceptable safety profile of
Fig. 2 Reductions from baseline in renal angiomyolipoma volume in
each study visit. The study ended as per protocol 1 year after first
patient enrolment, which explains the reduced number of patients
available at month 12
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sirolimus, with stomatitis and hypertriglyceridaemia as the
main adverse reactions [24]. The mTOR inhibition caused
by sirolimus was effective in reducing AML volume, with a
faster shrinkage at the beginning of treatment that was
likely related to its anti-angiogenic effect. These results sup-
port the role of mTOR inhibitors as promising treatment
alternatives for TSC-related AML, with a manageable safety
profile, adequate efficacy and less aggressiveness than other
therapeutic options currently available.
The authors acknowledge that the present trial has sev-
eral limitations that should be considered when interpret-
ing its findings, including the open-label and single-arm
design. Although the absence of a control group prevented
us from determining the magnitude of the effect, the
favourable data available on everolimus risk/benefit bal-
ance would have made the use of placebo unethical and
there was no alternative non-surgical standard therapy for
the disease. Local radiologists were involved in all CT/
MRI assessments and no independent central radiologic
review was conducted, which may have increased inter-
observer variability. Furthermore, this study could only
address the short-term effect of everolimus administration
and the reduced sample size of our study can be regarded
as another limitation. Nonetheless, our findings expand
the current information on the use of everolimus for this
relatively uncommon condition.
Conclusion
This trial supports the safety profile and clinical efficacy of
everolimus for the treatment of TSC-related AML re-
ported by previous clinical trials. Adverse events exhibited
over the study were as expected, without raising new
safety concerns, and were successfully managed with con-
comitant medication, dose reductions, and/or temporary
treatment interruptions. This manageable safety profile
enabled patients to remain under treatment with everoli-
mus, achieving benefits in terms of AML lesions and
kidney volumes. Reductions in these AML lesions and
kidney volumes were evident in the majority of patients a
few months after starting treatment, more than half
achieved radiologic AML response, and none progressed.
These findings expand the information currently available
on the use of everolimus for this condition and warrant
further assessments to optimize and prolong everolimus’
effect in routine clinical practice.
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